NeoProgen, Inc. is a preclinical-stage therapeutics company in Baltimore developing cell-based therapies for cardiovascular disease, including heart failure. The company reports access to rare tissues and a team of seasoned entrepreneurs and scientists. NeoProgen aims to pioneer a new treatment paradigm in heart failure and to create jobs and economic development for Baltimore if successful. Financially, NeoProgen completed a $1.5M seed funding round in 2019. The round was completed with a $245,000 investment from the University System of Maryland’s Maryland Momentum Fund and included participation from the University of Maryland, Baltimore (UMB), TEDCO’s Maryland Venture Fund (Maryland Venture Partners, L.P.), and UM Ventures.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2019